Abraxis BioScience Inc. (ABII) announced that the Office of Orphan Products Development of the Food and Drug Administration or FDA has granted orphan drug designation to the chemotherapy agent ABRAXANE for Injectable Suspension for the treatment of pancreatic cancer as well as stage IIB-IV melanoma.
Melanoma is an aggressive form of skin cancer that affects more than 68,000 people in the U.S. each year. Abraxis stated that it continues to study the potential of ABRAXANE in a variety of tumor types. ABRAXANE is a solvent-free chemotherapy treatment option for metastatic breast cancer, developed using Abraxis BioScience's proprietary nab technology platform.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.